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In a previous issue of Critical Care, Dankbaar and 
colleagues [1] presented a systematic review of clinical 
studies of hyperdynamic therapy and its components on 
cerebral blood ﬂ   ow (CBF). Symptomatic cerebral 
vasospasm is deﬁ  ned as cerebral ischemia attributable to 
narrowing of intracranial arteries and loss of cerebral 
autoregulation, and aﬄ   icts some 20 to 25% of patients 
after rupture of an intracranial aneurysm [2,3]. Th  e 
corner  stone of medical therapy for cerebral vasospasm is 
so-called hyperdynamic therapy. Also referred to as 
triple-H therapy, this strategy includes the use of hyper-
tension, hypervolemia, and hemodilution to optimize 
cerebral perfusion. Introduced in the 1970s, this manage-
ment strategy has become widely accepted as ﬁ  rst-line 
treatment for symptomatic vasospasm and is probably 
used in one form or another in nearly all neurosurgical 
centers. Indeed, this author favors the use of induced 
hypertension and volume supplementation for primary 
treatment of symptomatic vasospasm, prior to endo-
vascular treatment, and, anecdotally, has observed rapid 
neurological improvement - over the course of an hour or 
less - in such circumstances. Th  is acceptance of hyper-
dynamic therapy has evolved despite a relatively modest 
amount of supportive clinical evidence. Th  e recent 
American Heart Association Guidelines for the Manage-
ment of Aneurysmal Subarachnoid Hemorrhage described 
hyperdynamic therapy only as ‘one reasonable approach’ 
for the treatment of symptomatic vasospasm (Class IIa 
treatment eﬀ  ect, level of evidence B) [4]. Hyperdynamic 
therapy, particularly hypervolemic therapy, also comes 
with a price in terms of complications (reported in up to 
30% of cases [5,6]) and cost. Furthermore, it is not yet 
clear which components of hyperdynamic therapy are 
most important.
Dankbaar and colleagues [1] provide a systematic 
review of clinical studies of hyperdynamic therapy and its 
components on CBF. Why focus on CBF instead of 
neurological or overall clinical outcomes? An increase in 
cerebral perfusion is the mechanism by which hyper-
dynamic therapy is purported to exert its beneﬁ  cial 
eﬀ  ect, and increases in CBF have been linked to clinical 
improvement in patients with symptomatic vasospasm 
[7]. Also, an assortment of quantitative CBF measure-
ment techniques have appeared in the past two decades, 
permitting relatively precise and quantitative analyses of 
the eﬀ  ects of hyperdynamic therapy.
Dankbaar and coworkers found 11 studies; only one 
included a control group and the remaining studies 
compared CBF before and during treatment. Hypertension 
was associated with an increase in CBF in two of four 
studies examining hypertension alone, and one of two 
studies assessing triple-H therapy found an increase in 
CBF. Only one of seven studies of hypervolemia found a 
signiﬁ  cant increase in CBF compared to baseline. Hemo-
dilution did not change CBF. A meta-analysis of the 
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Complication rates were also diﬃ   cult to assess because 
they were included in only ﬁ  ve of the studies, although it 
is interesting that complication rates of zero were 
reported in two trials that included hypertension.
Th  e  ﬁ  ndings of this study are not surprising, as induced 
hypertension makes the most sense on a theoretical and 
practical basis. A key feature of cerebral vasospasm is loss 
of autoregulation [8,9], resulting in passive dependence 
of cerebral perfusion on systemic blood pressure. When 
loss of autoregulation is combined with a reduction in 
capacitance vessel caliber, cerebral perfusion becomes 
even more dependent on systemic blood pressure. It 
seems logical then that raising blood pressure is the most 
direct way to enhance CBF.
In contrast, hypervolemia is problematic because ﬂ  uid 
balance is a poor surrogate for circulating blood volume 
[10] and sustained volume expansion is diﬃ   cult  to 
maintain [11]. Hypervolemia also appears to be the 
compo  nent of hyperdynamic therapy most associated 
with complications, such as pulmonary edema, conges-
tive heart failure, and cerebral edema [11,12]. Since 
hypovolemia can also be hazardous in this setting, by 
exacerbating cerebral ischemia [11], maintenance of a 
normovolemic state may be the most prudent strategy. 
Hemodilution is even more problematic because the 
optimal hematocrit in patients with cerebral vasospasm 
is not known, and hemodilution has been associated with 
worsening of cerebral ischemia in clinical practice [13].
In addition to suggesting that hypertension may be the 
most eﬀ  ective component of hyperdynamic therapy, this 
review also hints that hypertension may actually be the 
safest component of hyperdynamic therapy. Much remains 
to be discovered, however. A wide array of diﬀ  erent 
options for hypertensive therapy exists; the clinician 
must choose a vasopressor (dobutamine, phenylephrine 
or dopamine), a method of assessment (systolic blood 
pressure, cerebral perfusion pressure, or pulmonary 
capillary wedge pressure), and a therapeutic goal. No 
technique of hypertensive therapy has yet been shown to 
be superior to others. Th  is is fertile ground for a well 
controlled, randomized trial. Based on their analysis, 
Dankbaar and coworkers managed to estimate that only a 
total of 104 subjects would be necessary for a two-armed 
trial of hypertensive therapy in patients with symptomatic 
cerebral vasospasm. Such a trial would be feasible and 
quick to complete.
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